Der ses ingen klinisk signifikante forskelle i rosiglitazons farmakokinetik hos patienter med nyresvigt eller terminal nyresygdom i kronisk dialyse.
There are no clinically significant differences in the pharmacokinetics of rosiglitazone in patients with renal impairment or end stage renal disease on chronic dialysis.